VIDEO: Blinatumomab marks improvement in pediatric B-cell acute lymphoblastic leukemia
Click Here to Manage Email Alerts
In this video, Daniel DeAngelo, MD, PhD, discusses the results of a study presented at ASH Annual Meeting that examined the addition of blinatumomab to standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia.
DeAngelo, chief of the division of leukemia at Dana-Farber Cancer Institute, highlighted the study, which saw “statistically significant” improvement in 3-year DFS for patients who received blinatumomab (Blincyto, Amgen).
“Here we have an example of the power of doing randomized studies, even in patients who do well, showing that you can continue to improve the outcome, and this will represent the standard of care, I believe, for pediatric patients,” DeAngelo said.
Reference:
- Rau RE, et al. Abstract 1. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.
Collapse
Healio Interviews
Click Here to Manage Email Alerts